Dengue Literature Review

Wan2012 - Autoimmunity in Dengue Pathogenesis

7 min read

Wan2012 - Autoimmunity in Dengue Pathogenesis

Full citation: Wan SW, Lin CF, Yeh TM, Liu CC, Liu HS, Wang S, Ling P, Anderson R, Lei HY, Lin YS. Autoimmunity in dengue pathogenesis. Journal of the Formosan Medical Association 112(1): 3–11 (2013). https://doi.org/10.1016/j.jfma.2012.11.006

Raw file: [[raw/wan2012.pdf]]

Summary

This review from the NCKU group (National Cheng Kung University, Taiwan) — the same laboratory behind Lin2006 - Autoimmune Pathogenesis in Dengue Virus Infection and Lin2011 - Molecular Mimicry Virus Host Dengue Pathogenesis — provides their most comprehensive synthesis of autoimmunity as a pathogenic mechanism in dengue. The paper positions autoimmunity as one of four immunopathogenic mechanisms (alongside ADE, cellular immune responses, and soluble factors) that, together with direct viral pathogenesis, produce the major manifestations of DHF: hemorrhage, thrombocytopenia, plasma leakage, and hepatomegaly (Fig. 1).

Beyond consolidating findings from Lin2006 and Lin2011, this review introduces several new elements: (1) the “intrinsic ADE” hypothesis, in which FcγR-mediated DENV entry suppresses type I IFN and promotes IL-10/Th2 skewing; (2) LYRIC protein as a new molecular mimicry target (NS1 aa 116–119 sharing sequence with LYRIC aa 334–337); (3) RGD structural mimicry in NS1 that blocks integrin-mediated cell adhesion despite the absence of an RGD sequence motif; (4) capsid (C) protein as a fourth dengue protein with coagulation factor homology; and (5) explicit temporal characterisation of dengue autoantibody kinetics — peak in acute phase, decline in convalescence, lasting several months — distinguishing dengue autoimmunity from chronic infection-associated autoimmune disease.

The paper is dedicated to Dr Huan-Yao Lei, who passed away during manuscript preparation. Lei was the senior figure in the NCKU dengue autoimmunity programme.

Study Design

  • Type: Narrative review, synthesising the NCKU group’s experimental programme (2001–2012) with broader literature
  • Sample size: N/A (review)
  • Setting: NCKU, Tainan, Taiwan; collaboration with Dalhousie University, Canada (Robert Anderson)
  • Population: N/A

Key Findings

Integrated pathogenesis model (Fig. 1)

  • Dengue pathogenesis involves both viral pathogenesis (virus variation, cell/tissue tropism) and immunopathogenesis (ADE, cellular immunity, soluble factors, autoimmunity)
  • All four immunopathogenic arms converge on the same clinical manifestations: hemorrhage, thrombocytopenia, plasma leakage, hepatomegaly
  • Autoimmunity is positioned as a co-equal mechanism alongside ADE, not subordinate to it

Intrinsic ADE hypothesis

  • FcγR-mediated DENV internalisation suppresses type I IFN-mediated antiviral responses by inhibiting antiviral gene expression
  • Simultaneously enhances IL-10 production, which suppresses IFN-γ signalling and promotes Th2 responses
  • Th2 skewing limits virus clearance (Th1-dependent) while enhancing antibody production — creating a feedback loop of high viral loads and high antibody titres
  • ADE also enhances cytokine/chemokine production, cell apoptosis, and TNF-α-mediated endothelial activation

New molecular mimicry targets

  • LYRIC (lysine-rich CEACAM1 co-isolated) protein: NS1 aa 116–119 shares sequence similarity with human LYRIC aa 334–337; anti-NS1 Abs may cross-react with LYRIC on endothelial cells
  • RGD structural mimicry: Despite the absence of an RGD (arginine-glycine-aspartic acid) sequence motif in NS1, RGD structural mimicry exists within the NS1 protein; anti-NS1 Abs can block RGD/integrin-mediated cell adhesion — relevant because RGD is critical for matrix-integrin interactions in vascular integrity
  • Capsid (C) protein: Added as a fourth dengue protein (alongside NS1, prM, E) showing homology with coagulatory molecules

Autoantibody kinetics

  • DENV-induced autoantibody titres peak in the acute phase, decline during convalescence, and persist for several months
  • This temporal profile is explicitly described as “different from chronic virus infection-associated autoimmune disease”
  • Reference to Garcia2009 (ref 97) for persistent clinical symptoms with ANA, immune complexes, CRP, and rheumatoid factor at 2 years — extending the kinetic window beyond “several months”

Case reports of dengue-triggered autoimmune disease

  • One case: dengue patient with numerous autoimmune features (Jardim et al. 2012)
  • One case: dengue evolving into systemic lupus erythematosus and lupus nephritis within one month (Rajadhyaksha & Mehra 2012)
  • These are cited as evidence that DENV infection can trigger frank autoimmune disease in individual cases, though population-level risk remains low

NS1 vaccine considerations

  • Anti-NS1 Abs fix complement and trigger complement-mediated lysis of DENV-infected cells — a protective mechanism
  • Active immunisation with NS1 or passive transfer of anti-NS1 Abs protects mice against DENV challenge
  • However, anti-NS1 Abs also cause pathogenic cross-reactivity (platelets, endothelium, coagulation)
  • Resolution: map and genetically manipulate the pathogenic epitopes (C-terminal aa 277–352) while preserving protective epitopes
  • A successful dengue vaccine must be effective against all four serotypes, avoid ADE, AND be free of autoimmune complications

Other immunopathogenic mechanisms reviewed

  • Original antigenic sin in T cells: low-affinity memory T cells from primary infection expand selectively during secondary heterotypic infection, producing inflammatory cytokines that drive plasma leakage
  • CD4+ cytotoxic T cells: DENV-specific CD4+ CTLs lyse bystander target cells in vitro; may explain hepatocyte damage
  • Regulatory T cells: increased Treg frequencies and Treg/effector T cell ratios in acute dengue — a new finding not previously in the wiki
  • Complement: C3a/C5a elevated in severe dengue; sNS1 and anti-DENV Abs activate complement on endothelial cell surfaces; factor D and H imbalance → alternative pathway deregulation in DHF
  • Cytokines/chemokines: IL-10 correlates with platelet loss; TNF-α triggers endothelial activation; MIF, MMP-9, MCP-1 promote permeability

Taiwan dengue epidemiology

  • Major outbreaks: 1981, 1987–88, 2001–02, 2007
  • DENV-2 predominated in 2002; primary DENV-1 or DENV-3 in 2004–2007
  • Dengue is primarily an adult disease in Taiwan: DF peaks in 50–54 age range; DHF peaks in 60–64 age range
  • Seasonal pattern: imported in early summer → local spread → ends in winter

Methods Used

  • N/A (narrative review; cites prior experimental work using proteomic analysis, absorption experiments, mouse models, cell culture assays, and patient sera)

Entities Mentioned

  • NS1 Protein (central focus; molecular mimicry, vaccine target, complement lysis)
  • E Protein (WGNGCG coagulation homology; subunit vaccine target)
  • DENV-2 (highest severity/mortality contribution)
  • DENV-3 (highest severity/mortality contribution alongside DENV-2)
  • Aedes aegypti (primary vector)
  • Aedes albopictus (secondary vector)

Concepts Addressed

Relevance & Notes

This paper is the capstone review of the NCKU autoimmunity programme, consolidating Lin2006 and Lin2011 into a unified pathogenesis model while adding new molecular mimicry targets (LYRIC, RGD structural mimicry, capsid protein). Its most important contribution to the wiki’s ANA-dengue research thread is the explicit temporal characterisation of dengue autoantibody kinetics: acute peak → convalescent decline → several months persistence. This time course directly informs the interpretation of Garcia2009 (ANA at 2 years) and Chatterjee2024 (54.8% ANA acutely): Wan2012 implies that the “several months” window is the expected resolution time for dengue autoantibodies, making Garcia2009’s 2-year persistence an outlier that requires explanation (FcγRIIa-HH genotype? Ongoing IC formation?).

The intrinsic ADE hypothesis (IFN-I suppression + IL-10/Th2 promotion) connects ADE to autoimmunity: by shifting toward Th2/antibody-dominant responses and suppressing antiviral IFN-I, intrinsic ADE creates conditions for enhanced autoantibody production alongside higher viral loads.

The paper is dedicated to Dr Huan-Yao Lei, indicating this is a memorial/legacy publication for the programme’s founder.

Questions Raised

  1. Do the new mimicry targets (LYRIC, RGD structural mimicry) produce functionally pathogenic autoantibodies in patients, or are they in vitro observations without clinical correlates?
  2. If dengue autoantibodies “last several months,” what mechanism extends ANA positivity to 2 years in the Garcia2009 cohort? Is it ongoing immune complex formation, FcγRIIa-HH-mediated clearance failure, or a different autoantibody population?
  3. Does the intrinsic ADE pathway (IFN-I suppression + IL-10 + Th2 skewing) preferentially generate autoantibodies vs. protective neutralising antibodies? If so, ADE and autoimmunity may be mechanistically linked rather than parallel.
  4. The case reports of dengue→SLE/lupus nephritis — are these exceptional cases driven by genetic predisposition, or does dengue carry a genuine (if tiny) risk of triggering clinical autoimmune disease? Shih2023 suggests the latter is not detectable at population level.

Graph View

Backlinks